These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 25592182)

  • 1. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
    Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
    Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "I Kicked the Hard Way. I Got Incarcerated." Withdrawal from Methadone During Incarceration and Subsequent Aversion to Medication Assisted Treatments.
    Maradiaga JA; Nahvi S; Cunningham CO; Sanchez J; Fox AD
    J Subst Abuse Treat; 2016 Mar; 62():49-54. PubMed ID: 26747509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does incarceration influence patients' goals for opioid use disorder treatment? A qualitative study of buprenorphine treatment in jail.
    Vail W; Faro E; Watnick D; Giftos J; Fox AD
    Drug Alcohol Depend; 2021 May; 222():108529. PubMed ID: 33810909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent incarceration and buprenorphine maintenance treatment outcomes among human immunodeficiency virus-positive patients.
    Riggins DP; Cunningham CO; Ning Y; Fox AD
    Subst Abus; 2017; 38(3):297-302. PubMed ID: 27715904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
    Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
    Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
    DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
    Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial.
    Rich JD; McKenzie M; Larney S; Wong JB; Tran L; Clarke J; Noska A; Reddy M; Zaller N
    Lancet; 2015 Jul; 386(9991):350-9. PubMed ID: 26028120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Just fighting for my life to stay alive": a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories.
    Hoffman KA; Thompson E; Gaeta Gazzola M; Oberleitner LMS; Eller A; Madden LM; Marcus R; Oberleitner DE; Beitel M; Barry DT
    Addict Sci Clin Pract; 2023 Mar; 18(1):16. PubMed ID: 36944998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study.
    Stopka TJ; Rottapel R; Friedmann PD; Pivovarova E; Evans EA
    Addict Sci Clin Pract; 2024 Sep; 19(1):68. PubMed ID: 39267138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perceptions of Community Corrections and Treatment Experience: A Qualitative Study Among People With Incarceration Histories Receiving Outpatient Methadone Treatment.
    Gaeta Gazzola M; Oberleitner LMS; Hoffman K; Eller A; Madden LM; Marcus R; Oberleitner D; Beitel M; Thompson E; Zheng X; Barry DT
    Subst Use Addctn J; 2024 Oct; 45(4):568-576. PubMed ID: 38551080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence.
    Godersky ME; Saxon AJ; Merrill JO; Samet JH; Simoni JM; Tsui JI
    Addict Sci Clin Pract; 2019 Mar; 14(1):11. PubMed ID: 30867068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "They're making it so hard for people to get help:" Motivations for non-prescribed buprenorphine use in a time of treatment expansion.
    McLean K; Kavanaugh PR
    Int J Drug Policy; 2019 Sep; 71():118-124. PubMed ID: 31330267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the Concepts of Abstinence and Recovery Through the Experiences of Long-Term Opiate Substitution Clients.
    Notley C; Blyth A; Maskrey V; Pinto H; Holland R
    Subst Abus; 2015; 36(2):232-9. PubMed ID: 25127184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incarceration and opioid withdrawal: the experiences of methadone patients and out-of-treatment heroin users.
    Mitchell SG; Kelly SM; Brown BS; Reisinger HS; Peterson JA; Ruhf A; Agar MH; Schwartz RP
    J Psychoactive Drugs; 2009 Jun; 41(2):145-52. PubMed ID: 19705676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study.
    Cheng A; Badolato R; Segoshi A; McDonald R; Malone M; Vasudevan K; Badiei B; Sugarman A; Macdonald R; Mangat J; Giftos J; Lee JD; Tofighi B
    Addict Sci Clin Pract; 2022 Jan; 17(1):4. PubMed ID: 35093164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
    Bishop B; Gilmour J; Deering D
    Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing need for medication-assisted treatment for opiate-dependent prison inmates.
    Albizu-García CE; Caraballo JN; Caraballo-Correa G; Hernández-Viver A; Román-Badenas L
    Subst Abus; 2012; 33(1):60-9. PubMed ID: 22263714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification.
    Uebelacker LA; Bailey G; Herman D; Anderson B; Stein M
    J Subst Abuse Treat; 2016 Jul; 66():48-53. PubMed ID: 27211996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing motivation within a rapid opioid substitution treatment feasibility RCT: a nested qualitative study.
    Ayres R; Ingram J; Rees A; Neale J; Beattie A; Telfer M
    Subst Abuse Treat Prev Policy; 2014 Nov; 9():44. PubMed ID: 25407020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.